IMPORTANCE Kidney stone disease is common and may be associated with an increased risk of coronary heart disease (CHD). Previous studies of the association between kidney stones and CHD have often not controlled for important risk factors, and the results have been inconsistent.
N ephrolithiasis is a common condition, with the prevalence varying by age and sex. A recent estimate from the National Health and Nutrition Examination Survey, a representative sample of the US population, reported the prevalence of a history of kidney stones of 10.6% in men and 7.1% in women. 1 The overall prevalence has increased from 3.8% (1976) (1977) (1978) (1979) (1980) 2 to 8.8% (2007) (2008) (2009) (2010) . 1 Associations between nephrolithiasis and systemic diseases have been recognized, including subclinical atherosclerosis, 3 hypertension, 4-6 diabetes, 7, 8 metabolic syndrome, 9 and cardiovascular disease. [10] [11] [12] One longitudinal study reported a 31% increased risk for myocardial infarction in patients with a history of kidney stones. 13 However, the other previously published studies either were cross-sectional, did not confirm clinical events, or did not take into account potential confounding by important risk factors such as dietary habits. Possible reasons for such association include shared risk factors, an increased incidence of kidney disease among patients with a history of kidney stones, 14 and abnormalities of calcium metabolism. 15 Therefore, we analyzed the relation between kidney stones and risk of incident coronary heart disease (CHD) for individuals with a history of kidney stones in 3 large prospective cohorts.
Methods

Study Populations
These studies were approved by the Partners HealthCare institutional review board, which accepts return of the questionnaires as implied consent in these cohorts. The Health Professionals Participants with a baseline self-reported history of myocardial infarction, coronary revascularization, or cancer (except nonmelanoma skin cancer) were excluded from the analysis. Participants who developed cancer during the follow-up were censored.
Assessment of Kidney Stones
Questions about history of kidney stones were first asked in 1986 for the HPFS cohort, in 1992 for the NHS I cohort, and in 1991 for the NHS II cohort. Subsequent biennial questionnaires asked about history of kidney stones in the previous 2 years. Participants reporting an incident kidney stone were asked to complete a supplementary questionnaire asking about the date of occurrence and symptoms such as pain or hematuria from the event. The self-reported diagnosis was confirmed in approximately 97% of participants who completed the additional questionnaire in 2 separate validation studies in these populations.
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Assessment of CHD
The primary outcome was CHD, defined as a composite of nonfatal or fatal myocardial infarction, fatal coronary heart disease, or coronary revascularization procedure (coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty). For simplicity, we defined fatal myocardial infarction as documented fatal myocardial infarction or fatal coronary heart disease determined by deaths identified from state death certificates or the National Death Index or reported by the participant's next of kin or the postal system. Fatal coronary heart disease was confirmed by an examination of hospital or autopsy records or if coronary heart disease was listed as the cause of death on the death certificate and the physician reviewers determined that coronary heart disease was the underlying and most plausible cause. Secondary outcomes were nonfatal or fatal myocardial infarction, and coronary revascularization, examined separately. Fatal and nonfatal myocardial infarction events were confirmed through medical record review and required characteristic symptoms with either diagnostic electrocardiographic changes or positive myocardial enzymes; revascularization was selfreported but has been found to be virtually 100% specific in the HPFS.
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Covariates
The following covariates were considered: race (white/ nonwhite); region of residence (West, Midwest, Northeast, South); family history of heart disease (yes/no); smoking status (never smoked, past smoker, current smoker); body mass index (BMI, calculated as weight in kilograms divided by height in meters squared; <20.0, 20.0-20.9, 21.0-21.9, 22.0-22.9, 23.0-23.9, 24.0-24.9, 25.0-26.9, 27.0-28.9, 29.0-29.9, 30.0-31.9, 32.0-34.9, 35.0-39.9, ≥40.0); physical activity (<3.0, 3.0-8.9, 9.0-17.9, 18.0-26.9, ≥27.0 metabolic equivalents/week); diabetes (yes/no); hypertension (yes/no); gout (yes/no); elevated cholesterol (yes/no); use of the following drugs (yes/no): aspirin, thiazide diuretics, loop diuretics, oral steroids, lipid-lowering drugs, calcium channel blockers, β-blockers, angiotensinconverting enzyme inhibitors, and other antihypertensive drugs; and daily intake of the following energy-adjusted nutrients (quintiles): calcium, potassium, magnesium, animal protein, total fat, vitamin D, caffeine, and alcohol (0, 0. For the purpose of the analysis, because the majority of the participants were white, race was coded as white/nonwhite and included in the analysis since race seems to be associated with both kidney stones and cardiovascular disease.
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To adjust for dietary patterns, we added the Dietary Approaches to Stop Hypertension (DASH) score to the model. Previous studies have shown that the DASH score is associated with a lower risk of kidney stone formation 22 and cardiovascular disease. 23 
Statistical Analysis
The time at risk started when history of kidney stones was first asked on the biennial questionnaires: 1986 for HPFS, 1992 for NHS I, and 1991 for NHS II. We calculated the person-years of follow-up for each participant from the start of the time at risk to the date of death, development of the outcome, or end of follow-up, whichever came first. The crude and adjusted hazard ratios (HRs) and 95% CIs for the development of a CHD event in participants with a history of kidney stones compared with those without were estimated with Cox proportional hazards regression models with biennial updating of history of kidney stones and covariates. For the composite CHD outcome, we used the first event when more than 1 coronary event occurred in the same period.
Interaction terms for history of kidney stones and age (≤50 or >50 years), BMI (<25 or ≥25), diabetes, and hypertension were included in separate models to explore possible effect modification. Furthermore, we analyzed whether including the intake of calcium supplements altered the association in a separate model.
Post hoc pooling of the results for the NHS I and NHS II cohorts was performed with random-effects meta-analysis.
A 2-tailed P-value less than .05 was considered statistically significant. All analyses were performed with SAS, version 9.3 (SAS Institute).
Results
After exclusions, a total of 242 105 participants (45 748 men and 196 357 women) were included in the analysis, contributing 3 994 120 person-years of follow-up. Of these, 19 678 had a history of kidney stones (10 827 at baseline and 8851 during follow-up). The median (25th-75th percentiles) follow-up times were 9.8 (5.3-15.8) years for HPFS, 8.2 (4.1-12.1) years for NHS I and 8.9 (4.9-13.1) years for NHS II. The overall number of participants developing incident CHD was 16 838.
The baseline characteristics of participants by cohort and exposure status are shown in Table 1 . The mean ages were 55.8 years for participants with a history of kidney stones and 53.7 years for participants without a history of kidney stones in HPFS; 59.0 years for participants with and 58.4 years for participants without in NHS I; and 37.4 years for participants with and 36.6 years for participants without in NHS II. High blood pressure, use of thiazides, and elevated cholesterol were more prevalent among participants with a reported history of kidney stones in all 3 cohorts, as well as diabetes in NHS I and gout in HPFS and NHS I. Intakes of calcium, caffeine, and vitamin D were lower in participants with a reported history of kidney stones.
The crude incidence rates of CHD per 100 000 personyears were 1355 among participants with and 1022 among participants without a history of kidney stones in the HPFS cohort (rate difference, 333/100 000 person-years); 754 among participants with and 514 among participants without in the NHS I cohort (rate difference, 240/100 000 person-years); and 144 among participants with and 55 among participants without in the NHS II cohort (rate difference, 89/100 000 person-years).
The crude incidence rates of myocardial infarction per 100 000 person-years were 536 among participants with and 432 among participants without a history of kidney stones in the HPFS cohort (rate difference, 104/100 000 person-years); 289 among participants with and 196 among participants without in the NHS I cohort (rate difference, 93/100 000 personyears); and 61 among participants with and 25 among participants without in the NHS II cohort (rate difference, 36/ 100 000 person-years).
The crude incidence rates of coronary revascularization per 100 000 person-years were 941 among participants with and 706 among participants without a history of kidney stones in the HPFS cohort (rate difference, 235/100 000 person-years); 605 among participants with and 401 among participants without in the NHS I cohort (rate difference, 204/100 000 person-years); and 107 among participants with and 40 among participants without in the NHS II cohort (rate difference, 67/100 000 person-years).
In age-adjusted analyses, there was a significant association between history of kidney stones and CHD in all the cohorts: HR, 1.18 (95% CI, 1. There was no significant interaction between history of kidney stones and age, BMI, or diabetes and the risk of CHD (P for interaction >.05 for all cohorts). The only significant interaction was with high blood pressure in HPFS (HR, 0.98 for participants with high blood pressure vs HR, 1.12 for participants without high blood pressure; P = .04) and NHS II (HR, 1.24 for participants with high blood pressure vs HR, 2.15 without high blood pressure; P = .01). The results did not change after including the intake of calcium supplements in the analysis.
Discussion
We found that a self-reported history of kidney stones was associated with a statistically significant increased risk of CHD in both cohorts of women (NHS I and NHS II), whereas no significant association was evident in the cohort of men (HPFS). One of the first reports of an association between nephrolithiasis and cardiovascular disease was by Elmfeldt and colleagues 11 in 1976, which compared the prevalence of selfreported history of kidney stones between 299 male survivors of myocardial infarction and a sample of the general population in Göteborg, Sweden.
The prevalence of kidney stones in the post-myocardial infarction group was 16.1% compared with 7.8% of the general population (P = .01). However, the results were only adjusted for age. 11 Similar studies in the same time frame, however, did not confirm this finding. To date, the only longitudinal study published on the risk of CHD in patients with kidney stones was by Rule and colleagues, 13 which compared the incidence of myocardial infarction in 4564 patients with kidney stones with 10 860 ageand sex-matched individuals without history of kidney stones. The diagnosis of kidney stones was based on diagnostic codes and that of myocardial infarction was confirmed through review of medical records. After a mean follow-up of 9 years, 96 individuals with kidney stones and 166 without kidney stones developed a myocardial infarction. The multivariableadjusted HR of developing myocardial infarction for individuals with stones compared with controls was 1.31 (95% CI, 1.02-1.69). The model was adjusted for many covariates but not for potentially important dietary risk factors or medications. For example, intake of calcium has been shown to be independently associated with incidence of kidney stones in an inverse manner 16 and with cardiovascular disease in a direct manner. 27 Also, potential confounding by drugs such as thiazides, which reduce calciuria and hence reduce the risk of developing kidney stones and also lower blood pressure thus potentially reducing the risk of CHD, 28 could not be ruled out.
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Even though the authors included alcohol dependence in their analysis, this could not be enough to rule out the possible confounding effect of moderate intake of alcohol. Furthermore, the number of outcomes was far lower than those in our study and only myocardial infarction was a study outcome. A potential explanation for the association between kidney stones and CHD is the relatively higher prevalence and incidence of cardiovascular risk factors in patients with stones, such as diabetes, 7, 29 hypertension, 5,30,31 metabolic syndrome, 9,32,33 and subclinical atherosclerosis. 3 However, even after adjusting for high blood pressure, diabetes, elevated cholesterol, and BMI in our analysis, the risk of developing CHD remained higher in individuals with a history of stones. Another proposed explanation may be the common influence of dietary factors (such as a low intake of calcium, which has been linked with both an increased risk of developing kidney stones 16, 17, 34 and hypertension 35 -a major risk factor for CHD). Again, the adjustment for dietary factors attenuated, but did not eliminate, the association in women, suggesting that this may not be the only explanation. A third possible explanation is related to the deterioration of kidney function related to kidney stones, 14, 36, 37 which in turn could cause an increase in cardiovascular morbidity and mortality. 38 We could not analyze kidney function in our analysis; however, the relation between history of nephrolithiasis and CHD remained significant after adjusting for chronic kidney disease in the analysis by Rule et al. 13 Finally, an impairment of the regulation of physiologic calcification has been postulated. Osteopontin is a glycoprotein involved in the formation and calcification of bone, and levels are increased in patients with CHD. 39 It is also an inhibitor of calcification in urine, and mice deficient in osteopontin have been shown to develop calcium oxalate stones after induction of hyperoxaluria. 40 A study in humans found significantly lower levels of urinary osteopontin in participants with a history of kidney stones compared with those without. 15 However, such findings were not replicated in another study. 41 Our findings of a positive association between history of kidney stones and subsequent coronary events might be explained by 3 possible scenarios: (1) the presence of an unknown inherent metabolic state (or unknown risk factors) that cause both kidney stones and CHD; (2) the presence of a stone might increase the risk independent of other known risk factors; and (3) residual confounding. We feel that the first scenario, namely kidney stones being an earlier marker of a common metabolic state or of shared risk factors that might subsequently lead to coronary events, is more biologically sound. However, further studies are needed to explore this and other possibilities.
Our finding of no significant association between history of kidney stones and risk of CHD in men but an increased risk in women is difficult to explain, even though we could not determine whether this was due to sex or some other difference between the male and female cohorts. However, differences by sex are not infrequent in studies analyzing the association between nephrolithiasis and either CHD or risk factors for CHD. For example, Domingos and Serra 10 found that, after adjusting for comorbidities, only women with a history of nephrolithiasis had increased odds of previous myocardial infarction. In the study by Hippisley-Cox and Coupland, 37 only women with a history of stone disease showed a significant increased risk of developing moderate to severe chronic kidney disease. Furthermore, Ando and colleagues 29 reported that the prevalence of diabetes in patients with kidney stones was significantly higher in women but not men, and the same has been reported for hypertension. 6 However, a large prospective study 42 challenged the traditional hypothesis of stone formation in favor of a vascular etiology. The authors hypothesized that the site of the initial lesion may be the vascular bed at the tip of the renal papilla, where vascular injury may give rise to calcification, which in turn may grow and erode through the papillary epithelium and become a nidus for stone formation. However, the lack of association in men does not support this hypothesis.
A limitation of our study may be the lack of generalizability, because the majority of the participants were white and race has an influence on both nephrolithiasis (with white populations being more prone to form stones compared with black and Hispanic populations) 2 and CHD (with higher incidence among black populations). 21 Also, we did not have information about stone composition for the majority of participants with a reported history of kidney stones, which could help establish etiological hypotheses, nor information about laboratory parameters such as serum creatinine to account for kidney function. The exclusion of individuals with a previous CHD event before baseline might have biased our findings toward the null. Additionally, many of the conditions included in the analysis (such as high blood pressure) were self-reported, though these have been validated and found to be reliable.
Conclusion
In conclusion, among 2 large cohorts of women, a history of kidney stones was associated with a modest but statistically significant increased risk of CHD; there was no significant association in a separate cohort of men. Further research is needed to determine whether the association is sex-specific and to establish the pathophysiological basis of this association.
ARTICLE INFORMATION
Author Contributions: Dr Ferraro had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
